"if he was your kids little league coach or scout leader, wouldn't you be a little concerned.??"
my guess is you are under 30 yo. With your current strategy/success record, how comfortable do you feel about the longevity of you endeavor?? Day trading is a tough way to make a living. TA exists as a crutch in an informational abyss. It works like the Bible... when others believe in it. Unless you a something really unique/special, you will won't last more than a couple of years...
but heck, I could be wrong.
that logic is called GAMBLING, and your odds will be roughly the same as a casino. Do you know what happens if you stay at the casino long enough???
I think it can be looked at in the same light as a engagement ring. They kinda locked up their options for only a billion dollars, and discouraged others' advances... of course I didn't read their agreement, so the "ironclad-ness" may be up to debate.
"Jefferies analyst David Steinberg upgraded the rating on Supernus Pharmaceuticals Inc (NASDAQ: SUPN) from Hold to Buy, after the company's Investor Day showcased its differentiated ADHD pipeline. During its Investor Day in NYC, the company showcased its key pipeline assets - SPN-810 and SPN-812. "We came away from the event more encouraged about the long-term growth prospects for these late-stage assets," analyst David Steinberg said, while adding, "We are particularly intrigued by the potentially broad IA indication for SPN-810 and believe it could become SUPN's largest drug." Globally 5-7 percent of children are estimated to have ADHD, while 22-32 percent of them also display IA. "The most common approach involves off-label utilization of atypical antipsychotics - which are plagued by undesirable side effects, poor tolerability and modest efficacy," Steinberg wrote. SPN-810 has exhibited robust results in Phase 2 testing and Supernus is currently finalizing a "3 trial pivotal program" with the FDA, scheduled to begin in 4Q15. "Importantly, while IA in ADHD is the first targeted indication, a broader IA label across autism, bipolar disorder and other CNS indications could eventually be secured - which would greatly expand the commercial opportunity if approved," the report mentioned. The limitations of stimulant therapies for ADHD are known, which means that SPN-812 has the potential to become "the leading non-stimulant ADHD drug if successfully developed," Steinberg added."
shorting merely based on the idea it 'might' be overvalued is a fool's game. Lots of stock are overvalued, and remain so, for a LONG time... but you seem to be smart.
"I dont get it" -- holywallst
you were spewing nonsense, like you knew ALL the answers!?!
pretty fun, huh?
most all retail shorts have no idea what they are doing and will settle before the end of the day.
while we agree, but not for the same rational...
- If you OWED a lot of money, and had control over the interest rate, what would be your priority?
- If you were the Guarantor of Last Resort for pensions, what would be your highest priority for the stock market?
ps: once you think you can play the market like a fiddle ... you're in trouble... maybe not today, but mark my words
I am going to put this in some terms, you might be able to understand... Assume in poker, that going all in, didn't stop someone else from betting more than you... How do you think it would change the outcome??
in some respect, the markets have been rigged since inception. The methods continuously mutate, but It has always been there. Deal with it, or sit out.
"per my visit with the ceo"
a comedian no less!
limited liquidity, afterhours short covering.
You (I ??) NEVER buy such events, but sales can be profitable
The biggest rule of investing I learned over the years, is don't invest a dime UNLESS you are willing to give it a year and a day. The second biggest rule of investing I learned over the years is never let a short term loss turn into a long term loss.
the high was hit yesterday afterhours, compliments of short covering... I wouldn't expect much change from where it sits right now... but heck, you might be right.